MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: Implications for the treatment of castration-resistant, bone-metastatic prostate cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Sarveswaran, Sivalokanathan ^a   Ghosh, Ritisha ^a   Morisetty, Shravan ^a   Ghosh, Jagadananda ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; QUIFLAPON; INDOLE DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PROTEIN KINASE B; QUINOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL KILLING; COLONY FORMING CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROTEIN EXPRESSION; TUMOR INVASION; BIOSYNTHESIS; BONE NEOPLASMS; DRUG EFFECTS; METASTASIS; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; INDOLES; LEUKOTRIENE ANTAGONISTS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION;

EID: 84928804761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122805     Document Type: Article

References (66)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29. doi: 10. 3322/caac.21208 PMID: 24399786
2. Marques RB, Dits NF, Erkens-Schulze S, Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. Plos one 2010; 5: e13500. doi: 10.1371/journal.pone.0013500 PMID: 20976069
3. Attard G, Sarker D, Reid A, Molife R, Parker C, et al. Improving the outcome of patients with castrationresistant prostate cancer through rational drug development. Br J Cancer 2006; 95: 767-774. PMID: 16983403
4. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009; 6: 76-85. doi: 10.1038/ncpuro1296 PMID: 19198621
5. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Eng J Med. 1989; 321: 419-424. PMID: 2503724
6. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 2007; 99:1056-1065. PMID: 17346277
7. Ryan CJ, Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it's a question of ''when?". J Clin Oncol. 2005; 23: 8242-8246. PMID: 16278479
8. Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J Urol. 2004; 171: 19-24.
9. Kolonel LN, Nomura AN, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst. 1999; 91: 414-428. PMID: 10070940
10. West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case control study with special emphasis on aggressive tumors. Cancer Causes Control 1991; 2: 85-94. PMID: 1873441
11. Giovannucci EL, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993; 85: 1571-1579. PMID: 8105097
12. Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, et al. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst. 1994; 86: 281-286. PMID: 8158682
13. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, et al. Decreased growth of established prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 1995; 87: 1456-1462. PMID: 7545759
14. Wynder EL, Rose DP, Cohen LA. Nutrition and prostate cancer: a proposal for dietary intervention. Nutr Cancer 1994; 22: 1-10. PMID: 11304906
15. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, et al. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 1995; 87: 1456-1462. PMID: 7545759
16. Rose DP. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr. 1997; 66: 1513S-1522S. PMID: 9394709
17. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun. 1997; 235: 418-423. PMID: 9199209
18. Ghosh J, Myers CE. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv Exp Med Biol. 1999; 469: 577-582. PMID: 10667385
19. Anderson KM, Seed T, Vos M, Mulshine J, Meng J, et al. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 1998; 37: 161-173. PMID: 9792133
20. Ghosh J, Myers C. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 13182-13187. PMID: 9789062
21. Ghosh J. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun. 2003; 307: 342-349. PMID: 12859962
22. Sarveswaran S, Myers CE, Ghosh J. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 30 -kinase. Cancer Lett. 2010; 291: 167-176. doi: 10.1016/j.canlet.2009.10.008 PMID: 19906484
23. Sarveswaran S, Thamilselvan V, Brodie C, Ghosh J. Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochim Biophys Acta 2011; 1813: 2108-2117. doi: 10.1016/j.bbamcr.2011.07.015 PMID: 21824498
24. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54: 2577-2581. PMID: 8168083
25. Prasit P, Belley M, Blouin M, Brideau C, Chan C, et al. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. J Lipid Mediat. 1993; 6: 239-244. PMID: 8357985
26. Depre M, Friedman B, Hecken AV, Lepeleire ID, Tanaka W, et al. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase activating protein inhibitor. Clin Pharmacol Ther. 1994; 56: 22-30. PMID: 8033491
27. Roberts WG, Simon TJ, Berlin RG, Haggitt RC, Snyder ES, et al. Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997; 112: 725-732. PMID: 9041233
28. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007; 317: 510-512. PMID: 17600184
29. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci. 2008; 29: 72-78. doi: 10. 1016/j.tips.2007.11.006 PMID: 18187210
30. Sarveswaran S, Ghosh J. OXER1, a G protein-coupled oxoeicosatranoid receptor, mediates the surviv-al-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cell. Cancer Lett. 2013; 336: 185-195. doi: 10.1016/j.canlet.2013.04.027 PMID: 23643940
31. Wolfer A, Ramaswamy S. Myc and metastasis. Cancer Res. 2011; 71: 2034-2037. doi: 10.1158/0008-5472.CAN-10-3776 PMID: 21406394
32. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, et al. Myc regulation of a "poor prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA 2010; 107: 3698-3703. doi: 10.1073/pnas.0914203107 PMID: 20133671
33. Wolfer A, Ramaswamy S. Prognostic signatures, cancer metastasis and MYC. Cell Cycle 2010; 9:3639. doi: 10.4161/cc.9.18.13220 PMID: 20930551
34. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010; 12: 247-256. doi: 10.1038/ncb2024 PMID: 20173740
35. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol. 2010; 12: 209-211. doi: 10.1038/ncb0310-209 PMID: 20173743
36. Civenni G, Malek A, Albino D, Garcia-Escudero1 R, Napoli S, et al. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res. 2013; 73: 6816-6827. doi: 10.1158/0008-5472.CAN-13-0615 PMID: 24063893
37. Koh CM, Bieberich CJ, Dang CV, Nelsonm WG, Yegnasubramanianm S, et al. MYC and prostate cancer. Genes Cancer 2010; 1: 617-628. doi: 10.1177/1947601910379132 PMID: 21779461
38. Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, et al. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol. 2011; 178: 1824-1834. doi: 10.1016/j.ajpath.2010.12.040 PMID: 21435462
39. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One 2012; 7: e29722. doi: 10.1371/journal.pone.0029722 PMID: 22235332
40. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, et al. Overexpression of c-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis. 2010; 13: 311-315. doi: 10.1038/pcan.2010.31 PMID: 20820186
41. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251. doi: 10. 1038/onc.2008.301 PMID: 18931691
42. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369: 156-160. PMID: 8177321
43. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem. 1996; 271: 24313-24316. PMID: 8798679
44. Maroney AC, Finn JP, Bozyczko-Coyne D, O'Kane TM, Neff NT, et al. CEP-1347 (KT 7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J Neurochem. 1999; 73: 1901-1912. PMID: 10537048
45. Nadeau PJ, Charette SJ, Landry J. REDOX reaction at ASK1-Cys250 is essential for activation of JNK and induction of apoptosis. Mol Biol Cell 2009; 20: 3628-3637. doi: 10.1091/mbc.E09-03-0211 PMID: 19570911
46. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, et al. Bcl-2 undergoes phosphorylation by the c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac. J Biol Chem. 1997; 272: 25238-25242. PMID: 9312139
47. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J Biol Chem. 2000; 275: 322-327. PMID: 10617621
48. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274. PMID: 17604717
49. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7: 606-619. PMID: 16847462
50. Marte BM, Downward J. PKB/Akt: connecting phosphoinositide3-kinase to cell survival and beyond. Trends Biochem Sci. 1997; 22: 355-358. PMID: 9301337
51. Altomare DA, Testa JR. Perturbations of the Akt signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464. PMID: 16288292
52. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4: 988-1004. PMID: 16341064
53. Tanaka A, Nishizaki T. The newly synthesized linoleic acid derivative FR236924 induces a long-Lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry Letters 2003; 13: 1037-1040. PMID: 12643906
54. Kanno T, Yamamoto H, Yaguchi T, Hi R, Mukasa T, et al. The linoleic acid derivative DCP-LA selectively activates PKC-å, possibly binding to the phosphatidylserine binding site. J. Lipid Res. 2006; 47: 1146-1156. PMID: 16520488
55. Uhl J, Klan N, Rose M, Entian KD, Werz O, et al. The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem. 2002; 277: 4374-4379. PMID: 11706027
56. Hoshiko S, Rådmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene promoter. Proc Natl Acad Sci USA 1990; 87: 9073-9077. PMID: 2251250
57. Sorg BL, Klan N, Seuter S, Dishart D, Rådmark O, et al. Analysis of the 5-lipoxygenase promoter and characterization of a vitamin D receptor binding site. Biochim Biophys Acta 2006; 1761: 686-697. PMID: 16750418
58. Klan N, Seuter S, Schnur N, Jung M, Steinhilber D. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity. Biol Chem. 2003; 384: 777-785. PMID: 12817474
59. Radmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci. 2007; 32: 332-341. PMID: 17576065
60. Radmark O, Samuelsson B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem Biophys Res Commun. 2010; 396: 105-110. doi: 10.1016/j.bbrc.2010.02.173 PMID: 20494120
61. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, et al. Bone-metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001; 47: 212-221. PMID: 11351351
62. Carson JP, Kulik G, Weber MJ. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/Protein Kinase B. Cancer Res. 1999; 59: 1449-1453. PMID: 10197612
63. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-193. doi: 10.1038/ nrc2809 PMID: 20168319
64. Ghosh J. Targeting 5-lipoxygenase for prevention and treatment of cancer. Curr Enzyme Inhib. 2008; 4: 18-28.
65. Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther. 2006; 112: 701-718. PMID: 16837050
66. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, et al. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001; 91: 737-743. PMID: 11241241